Vulpes Bio

1.9K posts

Vulpes Bio banner
Vulpes Bio

Vulpes Bio

@Vulpescap

B.S/PhD in Biology Former analyst at biotech-specialist HF Citizen of Graham and Doddsville VIC member Not investment advice, my opinions only

Beigetreten Nisan 2024
159 Folgt1.8K Follower
Vulpes Bio
Vulpes Bio@Vulpescap·
I remember when TACOs would give us 7% swings in the market. Now we get like 0.35%
English
0
0
3
43
Vulpes Bio
Vulpes Bio@Vulpescap·
@TweetAwayDK That said even efficacious antidepressants fail trials often due to pbo performance
English
0
0
1
24
Daniel Kim
Daniel Kim@TweetAwayDK·
@Vulpescap Ah, right. I read where you said there wasn’t any drug left on board at day 14, just didn’t connect that to what we see in the chart. Thanks
English
1
0
1
32
Vulpes Bio
Vulpes Bio@Vulpescap·
$PRTC too cheap at $400M FD IMO. UK-listed, low liquidity, doesn't look like anyone is paying attention. I think Seaport Tx's (PRTC owns 35% plus MSD royalties) MDD trial has a good chance to hit. I think brex/zuranolone works in MDD but $SAGE was flew too close to the sun with a 2wk PEP because that worked in PPD (but the MOA is a better fit for PPD). Seaport PEP at 6wks is the proper trial design. PRTC also owns a clinically validated IPF drug ready for Ph3 (chance to be best-in-class). SpinCo needs to raise. It's a free call option -- if they can't raise and this disappears, still cheap. PRTC also owns the dregs of the Cobenfy economics (2% royalty above $2B), probably worth $100-200M NPV. Full writeup here (do your own work)
Vulpes Bio tweet media
English
2
2
14
1.1K
Vulpes Bio
Vulpes Bio@Vulpescap·
@TweetAwayDK Doses only given til day 14, then thin efficacy dropped off at day 42. That's my point - SAGE should have dosed out to 6wks like Seaport is doing
English
1
0
0
40
Daniel Kim
Daniel Kim@TweetAwayDK·
@Vulpescap Appreciate the write-up. Chart seems to show zuranolone is no better than placebo at day 42; doesn't fit thesis that SPT-300 with similar efficacy but 6wk/42 day trial design will work. Pipeline generally feels "me-too", early stage, needs funding. Cobenfy is meh. Tough sell
English
1
0
0
52
Nikita Bier
Nikita Bier@nikitabier·
The full power of Grok on the algorithm launches next week. It will be the most important change we've done on X.
English
604
626
8.8K
931.9K
Rayne Wothbaum
Rayne Wothbaum@MelvinRiskMgmt·
Is there anything worse than the fckin Lancet subjournals for getting access? Even of these real academic libraries don't even pay for this ass lol
English
1
0
4
793
A.A
A.A@a_a_free·
Sorry I waited for this moment to troll you :p because you clearly did some misses on this one and it was 70% that it's gonna be approved. Well done on the previous hits but you got lucky because those companies are already shitcos. DNLI is well managed company and they know what they are doing.
Biotech Autist@BiotechAutist

1/ I’m SHORT $DNLI. They filed a safety study as their pivotal trial in the BLA. This application relies entirely on the clinical assumption that the FDA employs morons who treat uncontrolled substrate shifts like stone tablets from God.

English
1
0
11
3.8K